Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
absorption, ACB, acquiree, add, addressable, Addressing, afucosylated, aggressive, ALC, alive, anaplastic, anatomical, antibody, antigen, assign, bio, Biomanufacturing, BLA, Boston, Brentuximab, Brooklyn, Call, CC, chemokine, Chimeric, CMC, CMO, companion, conjugate, conjunction, correcting, corrective, CRL, CTCL, cycle, deacetylase, delete, denileukin, depletion, dexamethasone, diagnosed, diagnostic, diffuse, diftitox, diphtheria, Division, driven, DRL, duly, east, Eisai, elution, engineered, ensuing, Epidemiology, erythroderma, excluding, exfoliative, exhibit, exited, exploratory, extraction, extranodal, extremely, false, fifteen, formula, Freestanding, fusion, FY, halted, HDAC, Hillman, histone, Hodgkin, immunogenicity, immunotherapy, inclusion, indefinitely, India, inhibitor, Inline, instance, Interactive, Istodax, jointly, Letter, leukemic, Ligand, light, Linkbase, living, lung, lymphoma, marker, Masonic, master, maximal, MCB, merger, metastatic, MF, Mogamulizumab, monoclonal, MTD, NCI, necessitated, NHL, nodal, noncontrolling, older, omitted, onsite, ontak, orphan, ORR, oversee, Oxley, oxygenation, pcALCL, pediatric, pembrolizumab, persistent, Pittsburg, POC, Poteligeo, protein, PTCL, qualification, receptor, recurrent, Reddy, refractory, regimen, remestemcelL, renamed, resolution, rest, resubmission, Romidepsin, SA, Schema, SEER, Seragen, settled, shock, simulation, solid, SS, Subtopic, subtype, Task, Taxonomy, thereunto, tiered, tisagenlecleucel, title, tolerability, tolerated, top, toxicology, toxin, trend, tumor, unblinded, undersigned, variant, vedotin, ventilation, verified, voluntarily, Vorinostat, Waisman, wholly, XBRL, Zolinza
Removed:
accrue, Akrimax, banned, CE, cleared, cofounder, compensatory, competent, comprehensive, concentrated, consumer, continually, converted, deficiency, delegated, demand, demanding, Department, desist, deviate, Directive, disgorgement, dissemination, documented, dossier, doubt, enrichment, equally, exploitation, exported, fashion, fluctuate, fraudulent, fully, function, half, heavily, imported, imposition, impounding, initially, inspected, ISO, Justice, Labor, landmark, launched, lawful, lengthy, loaned, Medicaid, Ministry, misrepresentation, monetary, monthly, noncompliance, notified, overturn, plaintiff, prejudgment, privately, producing, promissory, promotional, punitive, receivable, recertification, recertified, refunded, regular, remediated, rental, repealed, restitution, revised, scrutinized, separation, sourcing, SOX, Standardization, submitting, suffered, treble, unfair, unjust, violate, violation, voice, volatile, Welfare
Filing tables
Filing exhibits
- 10-K Annual report
- 10.29 Form of Notice of Stock Option Grant and Stock Option Award Agreement
- 10.30 Asset Purchase Agreement
- 10.31 Amended and Restated License, Development and Commercialization Agreement
- 10.32 Amendment to Amended and Restated License, Development and Commercialization Agreement
- 10.33 Amendment No. 2 to Amended and Restated License, Development and Commercialization Agreement
- 21 Subsidiaries
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.s.c. 1350, As Adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
- Download Excel data file
- View Excel data file
Related press release
CTXR similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-1 (No.’s 333-224386, 333-226395, 333-230919, 333-233759, 333-237638 and 333-238975) and on Form S-3 (No’s. 333-252561, 333-253179, 333-255005 and 333-256063) of Citius Pharmaceuticals, Inc. of our report dated December 15, 2021, relating to the consolidated financial statements of Citius Pharmaceuticals, Inc., appearing in the Annual Report on Form 10-K for the year ended September 30, 2021.
/s/ Wolf & Company, P.C.
Wolf & Company, P.C.
Boston, Massachusetts
December 15, 2021